3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Withdrawn
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
17
Neoplasms
9
Head and Neck Neoplasms
9
Prostatic Neoplasms
7
Ovarian Neoplasms
6
Lung Neoplasms
5
Pancreatic Neoplasms
4
Endometrial Neoplasms
4
Urinary Bladder Neoplasms
3
Rectal Neoplasms
3
Oropharyngeal Neoplasms
3
Motor Activity
3
Kidney Neoplasms
3
Health Behavior
3
Depression
3
Carcinoma, Squamous Cell
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Smoking Cessation
2
Multiple Myeloma
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Communication
2
Colorectal Neoplasms, Hereditary Nonpolyposis
2
Carcinoma, Renal Cell
2
Anxiety Disorders
2
Alopecia
2
Xerostomia
1
Interventions
pembrolizumab
6
Paclitaxel
5
Carboplatin
4
Bevacizumab
3
oregovomab
2
Nivolumab
2
Hyperthermic Intraperitoneal Chemotherapy
2
Cisplatin
2
tislelizumab
1
spartalizumab
1
rucaparib
1
olaparib
1
niraparib
1
lenvatinib
1
fludarabine phosphate
1
fludarabine
1
denileukin diftitox
1
anlotinib
1
Surveys and Questionnaires
1
Saline Solution
1
Ramucirumab
1
Platinum
1
Nutrition Assessment
1
Neoadjuvant Therapy
1
Leucovorin
1
Irinotecan
1
Immunotherapy, Adoptive
1
Glucose
1
Gemcitabine
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Ovarian Epithelial
×
Surveys and Questionnaires
×
Clear all
NCT02124421
2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2
Active not recruiting
32 enrolled